Research programme: hydroxysteroid dehydrogenase inhibitors - Ipsen
Latest Information Update: 16 Jul 2016
At a glance
- Originator Ipsen
- Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Metabolic syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-syndrome in France
- 26 Jan 2007 Preclinical trials in Metabolic syndrome in France (unspecified route)